FindTrial
Sign In

comparison of different treatment modalities in management of wart

comparative study of efficacy of intralesional purified protein derivative (PPD) versus intralesional measles, mumps, and rubella (MMR) in management of multiple viral wart

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/012019
Enrollment
105
Registered
2018-02-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- multiple viral warts

Interventions

Intervention1: mumps, measles and rubella vaccine: 0.1 ml of MMR vaccine intralesional into the largest wart Intervention2: rubella vaccine: 0.1 ml of rubella vaccine intralesional into the largest wa

Sponsors

krishna b bhalala
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. multiple viral warts over the body

Exclusion criteria

Exclusion criteria: i. Pregnant and lactating mothers. ii. Immunocompromised patients. iii. Known hypersensitivity to antigens. iv. Ulcerated/inflamed/secondarily infected warts. v. Patients not consenting to the study

Design outcomes

Primary

MeasureTime frame
complete clearance of the lesionsTimepoint: lesion site will assessed at the end of 8 weeks—

Secondary

MeasureTime frame
side effects(pain, fever,severe odema)Timepoint: 2 weeks, 4 weeks and 6 weeks—

Countries

India

Contacts

Public ContactKrishna B Bhalala

k.j.somaiya medical college and research centre

kjderm@gmail.com8291256943

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026